Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results

Grants

Funding Acknowledgements

This study was supported by Biogen Idec Inc, which also provided funding for editorial support in the development of this manuscript. Biogen Idec reviewed the manuscript and provided feedback on the manuscript. The authors had full editorial control of the manuscript and provided their final approval of all content.